Brandywine Global Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brandywine Global Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31,532	Closed	-$1.47M	–	794
2022 Q3	$1.47M	Hold	31,532	–	–	0.01%	581
2022 Q2	$1.8M	Sell	31,532 -537,279	-94%	-$30.5M	0.02%	553
2022 Q1	$34.8M	Sell	568,811 -6,167	-1%	-$320K	0.25%	115
2021 Q4	$30.1M	Sell	574,978 -10,096	-2%	-$424K	0.22%	129
2021 Q3	$21.8M	Buy	585,074 +389,514	+199%	+$13.5M	0.16%	146
2021 Q2	$7.98M	Buy	+195,560	New	+$7.23M	0.06%	318
2020 Q1	–	Sell	-65,619	Closed	-$2.17M	–	887
2019 Q4	$2.17M	Buy	65,619 +8,062	+14%	+$96.8K	0.02%	523
2019 Q3	$430K	Sell	57,557 -13,312	-19%	-$128K	﹤0.01%	590
2019 Q2	$920K	Buy	70,869 +28,409	+67%	+$364K	0.01%	577
2019 Q1	$518K	Buy	+42,460	New	+$543K	﹤0.01%	571

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Brandywine Global Investment Management's ITCI Position: Q4 2022 in Review

Brandywine Global Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 31,532 shares — an estimated $1.47M sold.

Brandywine Global Investment Management first reported a position in ITCI in Q1 2019 and held it in 10 quarters. The position peaked at $34.8M in Q1 2022. 283 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

Brandywine Global Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
Brandywine Global Investment Management sold 31,532 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $1.47M.
Brandywine Global Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 10 quarters.
Brandywine Global Investment Management's Intra-Cellular Therapies Inc. position peaked at $34.8M in Q1 2022.
283 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on Brandywine Global Investment Management's 13F filing for Q4 2022, filed 10 Feb 2023.